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negative organisms are rare causes of IE.1,2 The most
common pathogen is Escherichia coli.1 E. coli endocarditis
occurs most frequently in immunocompromised elderly
women, especially those with diabetes mellitus. Urinary
tract infection is the most common initial event. Approxi-
mately 0.51% of IE cases are caused by E. coli, with a
mortality rate of 21%.2
Therapy for E. coli endocarditis is controversial. Previ-
ous literatures suggested that early valve replacement
should be considered for patients with E. coli endocarditis
to reduce the mortality rate.3 Indications for surgery
included valvular regurgitation, heart failure, emboliza-
tion, myocardial abscess, or persistent bacteremia.2 How-
ever, antimicrobial agents used alone have been successful
in treating some patients with E. coli endocarditis accord-
ing to recent studies.4
For medical therapy, Moreillon6 summarized the antibi-
otic suggestion for HACEK (Haemophilus species, Actino-
bacillus, Cardiobacterium, Eikenella and Kingella species)
IE as 4 weeks of ceftriaxone or ampicillin plus gentamicin
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reported that the median planned duration of antibiotics at
hospital discharge from the first effective dose was 42
days.2 The European Society of Cardiology guidelines rec-
ommended treatment with early surgery plus long-term (6
weeks) therapy with bactericidal combinations of b-lactams
and aminoglycosides,5 sometimes with additional quino-
lones or cotrimoxazole. Medical treatment of E. coli
endocarditis in the last 5 years has provided good survival
after 6 weeks of antibiotics therapy and/or surgical
intervention.
Herein, we report a case of 46-year-old woman with
bicuspid aortic valves and severe aortic regurgitation, who
initially presented with acute onset of dyspnea for 1 day.
Urinary analysis revealed pyuria. Chest X-ray showed acute
pulmonary edema. Empiric antibiotic therapy with cefta-
zidime was prescribed for 3 days; it was then changed to
piperacillin-tazobactam plus gentamicin. Four sets of blood
culture yielded E. coli, however, urine culture showed no
bacteria growth and sputum culture revealed mixed flora.
An ultrasound and computerized tomography of the
abdomen did not reveal any infectious focus. A trans-
esophageal echocardiogram revealed bicuspid aortic valves
with two vegetations over the aortic valve
(0.9 cm  0.5 cm, 0.6 cm  0.2 cm; Figure 1) and one
vegetation (0.3 cm  0.3 cm) over the anterior leaflet of
the mitral valve.
Surgical intervention was advised, but the patient hesi-
tated because of the high mortality related to severeAssociation. All rights reserved.
Figure 1 Transesophageal echocardiogram showing two
vegetations (arrows) over the aortic valves (0.9 cm  0.5 cm,
0.6 cm  0.2 cm, respectively). AoZ aorta; LAZ left atrium;
LV Z left ventricle.
894 C.-A. Chen et al.pulmonary hypertension. One week later, we switched
antibiotic therapy from piperacillin-tazobactam to cefta-
zidime (for 21 days) and kept gentamicin for 14 days. A
follow-up blood culture revealed no growth after 4 weeks
of antibiotic treatment. She remained well at the 8-month
follow-up visit after discharge.
We demonstrated that this patient with E. coli endo-
carditis recovered well with standard 4-week antibiotic
therapy. Most importantly, clinicians should consider the
possibility that patients with continuous E. coli bacteremiamay suffer from endocarditis rather than a more common
process such as urosepsis. Otherwise, diagnosis could be
missed, especially in patients with sustained fever, new-
onset heart murmur, and predisposing factors such as
being an elderly female, having diabetes mellitus, an
immunocompromised status, and previous valve disease. It
is recommended that early echocardiography should be
performed on selected patients with E. coli bacteremia to
identify those with endocarditis.References
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